Patents by Inventor Konrad Hochedlinger

Konrad Hochedlinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for reprogramming somatic cells
    Patent number: 11655459
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: May 23, 2023
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • DIRECT REPROGRAMMING OF SOMATIC CELLS INTO MYOGENIC CELLS
    Publication number: 20230042917
    Abstract: Described herein are methods of generating induced muscle progenitor cells (iMPCs) and uses thereof. Embodiments further provide for methods of promoting muscle regeneration and/or repair and methods of treating a muscle disease or disorder.
    Type: Application
    Filed: June 22, 2022
    Publication date: February 9, 2023
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Konrad HOCHEDLINGER, Ori BAR-NUR
  • METHODS FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20220403344
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Application
    Filed: August 29, 2022
    Publication date: December 22, 2022
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • METHODS FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20200239855
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Application
    Filed: October 28, 2019
    Publication date: July 30, 2020
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Methods for reprogramming somatic cells
    Patent number: 10457917
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: October 29, 2019
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • DIRECT REPROGRAMMING OF SOMATIC CELLS INTO MYOGENIC CELLS
    Publication number: 20190161731
    Abstract: Described herein are methods of generating induced muscle progenitor cells (iMPCs) and uses thereof. Embodiments further provide for methods of promoting muscle regeneration and/or repair and methods of treating a muscle disease or disorder.
    Type: Application
    Filed: April 6, 2017
    Publication date: May 30, 2019
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Konrad HOCHEDLINGER, Ori BAR-NUR
  • METHODS FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20190078057
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Application
    Filed: July 9, 2018
    Publication date: March 14, 2019
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • METHODS OF CONTROLLING CELL FATE AND CONSEQUENCES FOR DISEASE
    Publication number: 20180327745
    Abstract: Provided herein are methods for performing cellular reprogramming that include treatment of somatic cells with an inhibitor of CAF-1, Sumo2, Nutd21, or combinations thereof prior to or during a reprogramming procedure. Such inhibitors can improve both the speed and efficiency of cellular reprogramming. Inhibitors of the CAF-1 complex can also be used in the treatment of cancer.
    Type: Application
    Filed: July 24, 2018
    Publication date: November 15, 2018
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Konrad HOCHEDLINGER, Sihem CHELOUFI
  • Methods of controlling cell fate and consequences for disease
    Patent number: 10059945
    Abstract: Provided herein are methods for performing cellular reprogramming that include treatment of somatic cells with an inhibitor of CAF-1, Sumo2, Nutd21, or combinations thereof prior to or during a reprogramming procedure. Such inhibitors can improve both the speed and efficiency of cellular reprogramming. Inhibitors of the CAF-1 complex can also be used in the treatment of cancer.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: August 28, 2018
    Assignee: The General Hospital Corporation
    Inventors: Konrad Hochedlinger, Sihem Cheloufi, Marti Anne Borkent
  • Methods for reprogramming somatic cells
    Patent number: 10017744
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: July 10, 2018
    Assignee: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • METHODS FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20170240865
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • METHODS OF CONTROLLING CELL FATE AND CONSEQUENCES FOR DISEASE
    Publication number: 20170175120
    Abstract: Provided herein are methods for performing cellular reprogramming that include treatment of somatic cells with an inhibitor of CAF-1, Sumo2, Nutd21, or combinations thereof prior to or during a reprogramming procedure. Such inhibitors can improve both the speed and efficiency of cellular reprogramming. Inhibitors of the CAF-1 complex can also be used in the treatment of cancer.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 22, 2017
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Konrad HOCHEDLINGER, Sihem CHELOUFI, Marti Anne BORKENT
  • Methods for reprogramming somatic cells
    Patent number: 9670464
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: June 6, 2017
    Assignee: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • METHODS FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20160115456
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Application
    Filed: October 26, 2015
    Publication date: April 28, 2016
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Methods for reprogramming somatic cells
    Patent number: 9169490
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: October 27, 2015
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Compositions for identifying reprogramming factors
    Patent number: 8951797
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: February 10, 2015
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Methods for making somatic cells more susceptible to reprogramming
    Patent number: 8940536
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: January 27, 2015
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Methods for reprogramming somatic cells
    Patent number: 8932856
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 13, 2015
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Methods for reprogramming somatic cells
    Patent number: 8927279
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 6, 2015
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING
    Publication number: 20140120621
    Abstract: In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGF?R) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGF?R inhibitor. Further described herein are kits for producing iPS cells using a TGF?R inhibitor.
    Type: Application
    Filed: October 24, 2013
    Publication date: May 1, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Konrad Hochedlinger, Matthias Stadtfeld